간섬유증 치료제 시장 : 약제 클래스별, 작용기전별, 투여 경로별, 유통 채널별 시장 예측(2026-2032년)

The Liver Fibrosis Drugs Market is projected to grow by USD 30.71 billion at a CAGR of 8.68% by 2032.

Liver fibrosis drugs are moving from supportive disease management toward targeted intervention across metabolic dysfunction-associated steatohepatitis (MASH), viral hepatitis, alcohol-associated liver disease, cholestatic disorders, and autoimmune liver diseases. Fibrosis is clinically important because progressive scarring can lead to cirrhosis, portal hypertension, liver failure, and hepatocellular carcinoma, making earlier diagnosis and treatment central to specialty care pathways.

The market is being reshaped by the 2024 U.S. approval of resmetirom for noncirrhotic MASH with moderate-to-advanced fibrosis, which created the first approved therapy for this high-burden metabolic liver disease segment. Growth is also supported by noninvasive tests, elastography, biomarker panels, and trial designs that increasingly focus on fibrosis improvement without worsening steatohepatitis.

Transformative Shifts in the Liver Fibrosis Treatment Landscape

The liver fibrosis treatment landscape is shifting from late-stage cirrhosis management to earlier identification of patients with F2-F3 fibrosis. This transition is supported by wider use of transient elastography, MRI-based techniques, serum biomarkers, and risk stratification tools in hepatology, endocrinology, and primary care.

Drug development is also diversifying beyond single-mechanism antifibrotics. Developers are advancing metabolic modulators, thyroid hormone receptor beta agonists, GLP-1-based therapies, FXR agonists, FGF analogs, PPAR agonists, anti-inflammatory agents, and combination strategies. The result is a more competitive liver fibrosis drugs market where clinical differentiation depends on histology, noninvasive endpoints, safety, cardiometabolic benefit, and payer acceptance.

Cumulative Impact of Artificial Intelligence on Liver Fibrosis Drugs

Artificial intelligence is becoming a practical enabler across liver fibrosis drug discovery, clinical development, and patient identification. AI-supported image analysis can standardize histology interpretation, quantify fibrosis patterns, and reduce variability in biopsy assessment, while machine learning models can integrate laboratory values, imaging, genomics, and claims data to identify high-risk patients earlier.

In development programs, AI can improve site selection, trial recruitment, endpoint modeling, and real-world evidence generation. Its cumulative impact is strongest where it connects fragmented clinical data with noninvasive diagnostics, helping manufacturers demonstrate disease modification, optimize adherence programs, and build evidence packages for regulators and payers.

Key Regional Insights for Liver Fibrosis Drugs

North America remains a key commercial and regulatory reference point due to high metabolic disease prevalence, established hepatology networks, advanced diagnostic adoption, and the U.S. launch environment for the first approved MASH-directed therapy. Europe benefits from strong public health systems, guideline-driven care, and active clinical research, although reimbursement scrutiny and health technology assessment requirements can slow access in several countries.

Asia-Pacific is strategically important because of large patient pools, rising obesity and diabetes rates, persistent viral hepatitis burden in several markets, and expanding clinical trial infrastructure in China, India, Japan, South Korea, and Australia. Latin America, led by Brazil and Mexico, shows rising demand as metabolic liver disease recognition increases and specialist referral pathways improve, while the Middle East faces a substantial diabetes and obesity burden that supports screening and specialty care expansion. Africa presents long-term need linked to viral hepatitis, alcohol-related liver disease, and limited access to advanced diagnostics, making affordability, diagnostic reach, and health system capacity decisive for liver fibrosis treatment adoption.

Key Group Insights Across ASEAN, GCC, EU, BRICS, G7, and NATO

Across ASEAN, liver fibrosis drug demand is influenced by the dual burden of viral hepatitis and fast-rising metabolic disease, with Singapore, Thailand, Malaysia, Indonesia, Vietnam, and the Philippines expanding diagnostic and specialty care capacity at different speeds. GCC markets are shaped by high diabetes and obesity prevalence, strong hospital investment, and government-led specialty care modernization, creating demand for liver fibrosis diagnostics, hepatology services, and evidence-based pharmacologic options.

The European Union offers scale through centralized regulatory pathways, coordinated pharmacovigilance, and sophisticated health technology assessment, while BRICS countries combine large untreated populations with local manufacturing capacity, expanding clinical trial participation, and increasing public health focus on hepatitis and metabolic liver disease. G7 markets remain the benchmark for premium drug launches, evidence standards, and payer negotiation. NATO countries overlap heavily with North American and European systems, where supply security, data governance, and resilient pharmaceutical value chains are increasingly important for liver fibrosis drug access and continuity of care.

Key Country Insights for Liver Fibrosis Drug Commercialization

The United States leads in commercial opportunity because of specialty access, high MASH prevalence, broad use of advanced diagnostics, and rapid uptake potential for approved and late-stage therapies. Canada offers structured reimbursement, strong academic hepatology centers, and organized specialist networks, while Mexico and Brazil represent growing Latin American opportunities as metabolic disease, obesity, diabetes, and specialist referral networks expand.

In Europe, the United Kingdom, Germany, France, Italy, and Spain are central to adoption, with Germany often important for early European market access and France, Italy, Spain, and the United Kingdom emphasizing cost-effectiveness, guideline alignment, and real-world outcomes. Russia remains clinically relevant due to liver disease burden, though market access is affected by geopolitical, reimbursement, and supply constraints.

China and India provide major long-term volume potential due to population scale, diabetes growth, obesity trends, and hepatitis-related fibrosis, while Japan and South Korea offer advanced diagnostics, aging populations, and strong clinical research environments. Australia remains attractive for early diagnosis programs, high-quality trial infrastructure, specialist-driven adoption, and public health attention to metabolic liver disease.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize therapies with clear fibrosis benefit, favorable cardiometabolic profiles, and safety suitable for chronic use. Development plans should integrate noninvasive biomarkers, histology where required, real-world evidence, and patient segmentation by etiology, fibrosis stage, and metabolic risk.

Commercial teams should invest in hepatology-endocrinology referral pathways, payer evidence, diagnostic partnerships, and physician education. Organizations that combine drug efficacy with scalable patient identification, adherence support, and region-specific pricing strategies will be best positioned in the liver fibrosis drugs market.

Research Methodology

This executive summary is based on secondary research from regulatory announcements, clinical trial registries, peer-reviewed hepatology literature, public health agencies, product labels, and recognized medical guidelines. Findings were cross-checked across therapeutic mechanisms, disease etiologies, regulatory milestones, regional care patterns, and market access factors.

The methodology emphasizes verified evidence over speculative sizing. Analysis considers drug class innovation, approved therapy benchmarks, clinical endpoints, noninvasive diagnostics, patient identification barriers, reimbursement dynamics, and regional differences in liver disease burden and health system readiness.

Conclusion

The liver fibrosis drugs market has entered a more actionable phase as approved MASH therapy, stronger diagnostics, and diversified pipelines converge. The opportunity extends beyond a single disease label, spanning metabolic, viral, alcohol-related, cholestatic, and autoimmune causes of fibrosis.

Success will depend on proving durable fibrosis improvement, identifying patients before cirrhosis, and demonstrating value to payers. Industry participants that align clinical innovation with AI-enabled diagnostics, regional access strategies, and real-world evidence will shape the next decade of liver fibrosis treatment.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Liver Fibrosis Drugs Market, by Drug Class

• 7.1. Biologic Therapies
  • 7.1.1. Monoclonal Antibodies
  • 7.1.2. Recombinant Proteins
• 7.2. Cell Therapies
• 7.3. Gene Therapies
• 7.4. Small Molecule Inhibitors
  • 7.4.1. Natural Products
  • 7.4.2. Synthetic Compounds

8. Liver Fibrosis Drugs Market, by Mechanism Of Action

• 8.1. ASK1 Inhibitors
• 8.2. Galectin-3 Inhibitors
• 8.3. PPAR Agonists
  • 8.3.1. PPAR Alpha
  • 8.3.2. PPAR Delta
  • 8.3.3. PPAR Gamma
• 8.4. TGF Beta Blockers

9. Liver Fibrosis Drugs Market, by Route Of Administration

• 9.1. Injectable
  • 9.1.1. Intravenous
  • 9.1.2. Subcutaneous
• 9.2. Oral

10. Liver Fibrosis Drugs Market, by Distribution Channel

• 10.1. Hospital Pharmacy
• 10.2. Online Pharmacy
• 10.3. Retail Pharmacy
  • 10.3.1. Chain Pharmacy
  • 10.3.2. Independent Pharmacy

11. Liver Fibrosis Drugs Market, by Region

• 11.1. Asia-Pacific
• 11.2. North America
• 11.3. Latin America
• 11.4. Europe
• 11.5. Middle East
• 11.6. Africa

12. Liver Fibrosis Drugs Market, by Group

• 12.1. ASEAN
• 12.2. GCC
• 12.3. European Union
• 12.4. BRICS
• 12.5. G7
• 12.6. NATO

13. Liver Fibrosis Drugs Market, by Country

• 13.1. United States
• 13.2. Canada
• 13.3. Mexico
• 13.4. Brazil
• 13.5. United Kingdom
• 13.6. Germany
• 13.7. France
• 13.8. Russia
• 13.9. Italy
• 13.10. Spain
• 13.11. China
• 13.12. India
• 13.13. Japan
• 13.14. Australia
• 13.15. South Korea

14. Competitive Landscape

• 14.1. Market Concentration Analysis, 2025
  • 14.1.1. Concentration Ratio (CR)
  • 14.1.2. Herfindahl Hirschman Index (HHI)
• 14.2. Recent Developments & Impact Analysis, 2025
• 14.3. Product Portfolio Analysis, 2025
• 14.4. Benchmarking Analysis, 2025

15. Company Profiles

• 15.1. Akero Therapeutics, Inc.
• 15.2. Alentis Therapeutics AG
• 15.3. Alnylam Pharmaceuticals, Inc.
• 15.4. AstraZeneca PLC
• 15.5. Boehringer Ingelheim International GmbH
• 15.6. Bristol-Myers Squibb Company
• 15.7. Cirius Therapeutics, Inc.
• 15.8. Eli Lilly and Company
• 15.9. FibroGen, Inc.
• 15.10. Galectin Therapeutics, Inc.
• 15.11. Gilead Sciences, Inc.
• 15.12. Hepion Pharmaceuticals, Inc.
• 15.13. Intercept Pharmaceuticals, Inc.
• 15.14. Inventiva Pharma
• 15.15. Ionis Pharmaceuticals, Inc.
• 15.16. Madrigal Pharmaceuticals, Inc.
• 15.17. Merck & Co., Inc.
• 15.18. NorthSea Therapeutics B.V.
• 15.19. Novartis AG
• 15.20. Novo Nordisk A/S
• 15.21. Pfizer Inc.
• 15.22. Pharmaxis Ltd.
• 15.23. Pliant Therapeutics, Inc.
• 15.24. Sagimet Biosciences Inc.
• 15.25. Takeda Pharmaceutical Company Limited
• 15.26. Zydus Lifesciences Limited